Clinical

Dataset Information

A randomized phase II study of UFT/LV or TEGAFOX for patient with curatively resected high risk Stage II and Stage III colorectal cancer.


ABSTRACT: Interventions: UFT(300mg/m2)+LV(75mg) /day, orally 4 weeks on and 1 week off in each corse. Total 5 weeks. UFT(300mg/m2)+LV(75mg) /day, orally 4 weeks on and 1 week off in each corse. Total 5 weeks. Oxaliplatin gives 85 mg/m2 intravenously on 1,15 day of each course. Primary outcome(s): 3-year desiese free survival rate Study Design: Parallel Randomized

DISEASE(S): High Risk Stage Ii/ Stage Iii Colorectal Cancer

PROVIDER: 2623111 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR